Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pectuna vs Perjeta in Neoadjuvant HER2+ Breast Cancer
NCT04957212Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Aug 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab + pertuzumab in HER2-positive breast cancer, sponsored by CinnaGen. Started Aug 2018; status: completed.
02
Drugs
trastuzumab + pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04957212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04957212.